

PERSONAL DETAILS

Mazzarelli Chiara, MD

 chiara.mazzarelli@ospedaleniguarda.it

Sex Female

Date of birth 08/08/1983

Nationality Italian

Registration Ordine dei Medici di Milano 44791

EDUCATION AND TRAINING

2019-2023	PHD in Hepatology, Università La Sapiena (Roma, Italy)
2014-2015	Post-graduate course in Advanced Hepatology and Transplant, Università Milano Bicocca (Milan, Italy)
2008–2013	Registrar at Hepatology and Internal Medicine, Università Campus Biomedico (Rome, Italy)
2007	Bachelor (magna cum laude) of Medicine and Surgery, Università Campus Biomedico (Rome, Italy)
2001-2007	Medical School, Università Campus Biomedico (Rome, Italy)

WORK EXPERIENCE

From October 2018-Present	Permanent Consultant, Hepatology and Gastroenterology at Niguarda Hospital (Milan)
From May 2013 – October 2018	Locum Consultant, Hepatology and Gastroenterology at Niguarda Hospital (Milan)
From March 2013 to May 2013	Clinical Fellow in Hepatology and Liver Unit at Università Campus Biomedico (Rome)

RESEARCH EXPERIENCES

- From Jan 2017 to Dec 2017 Clinical Research Fellow at King's College Hospital, Institute of Liver studies (London, UK).
- From May 2006 to July 2007 Training fellow at Virology Lab of Università Campus Biomedico (Rome, Italy) where I acquired expertise in laboratory techniques (ELISA, PCR, Immunoblotting).
- From Oct 2012 to Feb 2013 Training fellow at the Ultrasound and Interventional radiology, Ospedale S. Donato (Arezzo, Italy).

MEMBERSHIP

AISF member
EASL member
AASLD member
ESOT Member

QUALIFICATIONS

Management of advanced liver diseases and its complications (ascites, variceal bleeding, encephalopathy)
Management of end stage liver disease, ACLF and acute liver failure
Management of antiviral therapy for chronic hepatitis C in advanced liver disease (Child B-C), pre-transplant e post-transplant setting
Qualified expertise in ultrasound (including fibroscan and ARFI) and in interventional ultrasound (liver biopsies, nodular biopsies, PEI)

PUBLICATIONS

Bang K, Casadei-Gardini A, Yoo C, Iavarone M, Ryu MH, Park SR, Kim HD, Yoon YI, Jung DH, Park GC, Ahn CS, Moon DB, Hwang S, Kim KH, Song GW, **Mazzarelli C**, Alimenti E, Chan SL, De Giorgio M, Ryoo BY, Lee SG. Efficacy and safety of lenvatinib in patients with recurrent hepatocellular carcinoma after liver transplantation. Cancer Med. 2023 Feb;12(3):2572-2579.

Guarino M, Cossiga V, Capasso M, **Mazzarelli C**, Pelizzaro F, Sacco R, Russo FP, Vitale A, Trevisani F, Cabibbo G, On Behalf Of The Associazione Italiana Per Lo Studio Del Fegato Aisf Hcc Special Interest Group. Impact of SARS-CoV-2 Pandemic on the Management of Patients with Hepatocellular Carcinoma. *J Clin Med.* 2022 Jul 31;11(15):4475.

Rossotti R, Merli M, **Mazzarelli C**, De Carlis RM, Travi G, Vecchi M, Viganò R, Lauterio A, Raimondi A, Belli LS, De Carlis LG, Puoti M. Similar survival but higher and delayed hepatocellular carcinoma recurrence in HIV-positive compared to negative cirrhotics undergoing liver transplantation. *Dig Liver Dis.* 2022 May 26:S1590-8658(22)00500-X.

Artzner T, Bernal W, Belli LS, Conti S, Cortesi PA, Sacleux SC, Pageaux GP, Radenne S, Trebicka J, Fernandez J, Perricone G, Piano S, Nadalin S, Morelli MC, Martini S, Polak WG, Zieniewicz K, Toso C, Berenguer M, Iegri C, Invernizzi F, Volpes R, Karam V, Adam R, Faitot F, Rabinowich L, Saliba F, Meunier L, Lesurtel M, Uschner FE, Michard B, Coilly A, Meszaros M, Poinot D, Besch C, Schnitzbauer A, De Carlis LG, Fumagalli R, Angeli P, Arroyo V, Fondevila C, Duvoux C, Jalan R; ELITA/EF-CLIF Working Group. Location and allocation: Inequity of access to liver transplantation for patients with severe acute-on-chronic liver failure in Europe. *Liver Transpl.* 2022 Sep;28(9):1429-1440.

Corradi M, **Mazzarelli C**, Cesari M, Viganò R, Belli LS.. Implementation of the frailty assessment to improve liver transplant outcomes. *Aging Clin Exp Res.* 2022 Apr 5:1-5. doi: 10.1007/s40520-022-02111-1

Germani G, Angrisani D, Addolorato G, Merli M, **Mazzarelli C**, Tarli C, Lattanzi B, Panariello A, Prandoni P, Craxì L, Forza G, Feltrin A, Ronzan A, Feltracco P, Grieco A, Agnes S, Gasbarrini A, Rossi M, De Carlis L, Francesco D, Cillo U, Belli LS, Burra P. Liver transplantation for severe alcoholic hepatitis: A multicenter Italian study. *Am J Transplant.* 2022 Apr;22(4):1191-1200.

Belli LS, Duvoux C, Cortesi PA, Facchetti R, Iacob S, Perricone G, Radenne S, Conti S, Patrono D, Berlakovich G, Hann A, Pasulo L, Castells L, Faitot F, Detry O, Invernizzi F, Magini G, De Simone P, Kounis I, Morelli MC, Díaz Fontenla F, Ericzon BG, Loinaz C, Johnston C, Gheorghe L, Lesurtel M, Romagnoli R, Kollmann D, Perera MTP, Fagioli S, Mirza D, Coilly A, Toso C, Zieniewicz K, Elkrief L, Karam V, Adam R, den Hoed C, Merli M, Puoti M, De Carlis L, Oniscu GC, Piano S, Angeli P, Fondevila C, Polak WG; for all the centres contributing to the ELITA-ELTR COVID-19 Registry. COVID-19 in liver transplant candidates: pretransplant and post-transplant outcomes - an ELITA/ELTR multicentre cohort study. *Gut.* 2021 Oct;70(10):1914-1924. doi: 10.1136/gutjnl-2021-324879

Belli LS, Duvoux C, Artzner T, Bernal W, Conti S, Cortesi PA, Sacleux SC, Pageaux GP, Radenne S, Trebicka J, Fernandez J, Perricone G, Piano S, Nadalin S, Morelli MC, Martini S, Polak WG, Zieniewicz K, Toso C, Berenguer M, Iegri C, Invernizzi F, Volpes R, Karam V, Adam R, Faitot F, Rabinovich L, Saliba F, Meunier L, Lesurtel M, Uschner FE, Fondevila C, Michard B, Coilly A, Meszaros M, Poinot D, Schnitzbauer A, De Carlis LG, Fumagalli R, Angeli P, Arroyo V, Jalan R; ELITA/EF-CLIF working group.. Liver transplantation for patients with acute-on-chronic liver failure (ACLF) in Europe: Results of the ELITA/EF-CLIF collaborative

study (ECLIS).. J Hepatol. 2021 Sep;75(3):610-622. doi: 10.1016/j.jhep.2021.03.030. Epub 2021 May 2..

Fabbiani M, Lombardi A, Colaneri M, Del Poggio P, Perini P, D'Ambrosio R, Degasperi E, Dibenedetto C, Giorgini A, Pasulo L, Maggiolo F, Castelli F, Brambilla P, Spinelli O, Re T, Lleo A, Rumi M, Uberti-Foppa C, Soria A, Aghemo A, Lampertico P, Baiguera C, Schiavini M, Faggioli S, Bruno R; NAVIGATORE-Lombardia Study Group. Share. High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting. J Viral Hepat. 2021 Mar;28(3):558-568.

Mazzarelli C, Angrisani D, Viganò R. The Rising Tide of Nonalcoholic Fatty Liver Disease: How Much Time Until the Flood Reaches Our Coast? Clin Gastroenterol Hepatol. 2020 Aug 4:S1542-3565(20)30987-3.

Caraceni P, Tufoni M, Zaccherini G, Riggio O, Angeli P, Alessandria C, Neri S, Foschi FG, Levantesi F, Airoidi A, Simone L, Svegliati-Baroni G, Faggioli S, Laffi G, Cozzolongo R, Di Marco V, Sangiovanni V, Morisco F, Toniutto P, Gasbarrini A, De Marco R, Piano S, Nardelli S, Elia C, Roncadori A, Baldassarre M, Bernardi M; ANSWER Study Investigators. On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites. J Hepatol. 2020 Aug 24:S0168-8278(20)33551-0.

Mazzarelli C, Viganò R, Vangeli M, Vanzulli A. An atypical presentation of biliary cast syndrome (BCS). Dig Liver Dis. 2020 Aug 17:S1590-8658(20)30388-1.

Manini MA, Bruce M, Whitehouse G, Mazzarelli C, Considine A, Agarwal K, Suddle A, Faggioli S, Heaton N, Heneghan M. A Very Short Course of HBIG+NA Followed by Entecavir or Tenofovir Monotherapy Prevents HBV Recurrence in Low-Risk Liver Transplant Recipients. Transplant Proc. 2020 Jun 28:S0041-1345(19)31356-9.

Calvaruso V, Mazzarelli C, Milazzo L, Badia L, Pasulo L, Guaraldi G, Lionetti R, Villa E, Borghi V, Carrai P, Alberti A, Biolato M, Piai G, Persico M, Santantonio T, Felder M, Angelico M, Montalbano M, Mancusi RL, Grieco A, Angeli E, D'Offizi G, Faggioli S, Belli L, Verucchi G, Puoti M, Craxi A. Daclatasvir-based regimens in HCV cirrhosis: experience from the Italian early access program. Sci Rep. 2019 Jan 24;9(1):585

Italian association for the study of the liver (AISF). AISF position paper on HCV in immunocompromised patients. Dig Liver Dis. 2019 Jan;51(1):10-23.

Mazzarelli C, Vangeli M, Airoidi A. Reply to "Harmful and Beneficial Effects of Anticoagulants in Patients With Cirrhosis and Portal Vein Thrombosis". Clin Gastroenterol Hepatol. 2019 Mar;17(4):797-798.

Mazzarelli C, Cannon MD, Hudson M, Heaton N, Sarker D, Kane P, Quaglia A, Suddle A. Hepatocellular Carcinoma as a complication of vascular disease of the liver after Fontan procedure. Hepatology. 2019 Feb;69(2):911-913.

Caraceni P, Riggio O, Angeli P, Alessandria C, Neri S, Foschi FG, Levantesi F, Airoidi A, Boccia S, Svegliati-Baroni G, Faggioli S, Romanelli RG, Cozzolongo R, Di Marco V, Sangiovanni V, Morisco F, Toniutto P, Tortora A, De Marco R, Angelico M, Cacciola

I, Elia G, Federico A, Massironi S, Guarisco R, Galioto A, Ballardini G, Rendina M, Nardelli S, Piano S, Elia C, Prestianni L, Cappa FM, Cesarini L, Simone L, Pasquale C, Cavallin M, Andrealli A, Fidone F, Ruggeri M, Roncadori A, Baldassarre M, Tufoni M, Zaccherini G, Bernardi M; ANSWER Study Investigators. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. *Lancet*. 2018 Jun 16;391(10138):2417-2429.

Mazzarelli C, Considine A, Childs K, Carey I, Manini MA, Suddle A, Dusheiko G, Agarwal K, Cannon MD. Efficacy and Tolerability of Direct-Acting Antivirals for Hepatitis C in Older Adults. *J Am Geriatr Soc*. 2018 Jul;66(7):1339-1345.

Mazzarelli C, Prentice WM, Heneghan MA, Belli LS, Agarwal K, Cannon MD. Palliative care in end stage liver disease: time to do better? *Liver Transpl*. 2018 Jul;24(7):961-968.

Perricone G, Duvoux C, Berenguer M, Cortesi PA, Vinaixa C, Facchetti R, Mazzarelli C, Rockenschaub SR, Martini S, Morelli C, Monico S, Volpes R, Pageaux GP, Fagioli S, Belli LS; European Liver and Intestine Transplant Association (ELITA). Delisting HCV-infected liver transplant candidates who improved after viral eradication: Outcome 2 years after delisting. *Liver Int*. 2018 May 11. doi: 10.1111/liv.13878.

Cortesi PA, Belli LS, Facchetti R, Mazzarelli C, Perricone G, De Nicola S, Cesana G, Duvoux C, Mantovani LG, Strazzabosco M. The optimal timing of Hepatitis C therapy in liver transplant eligible patients: cost-effectiveness analysis of new opportunities. *J Viral Hepat*. 2018 Feb 6. (epub ahead of print)

Martini S, Donato MF, Mazzarelli C, Rendina M, Visco-Comandini U, Fili D, Gianstefani A, Fagioli S, Melazzini M, Montilla S, Pani L, Petraglia S, Russo P, Trotta MP, Carrai P, Caraceni P; ITACOPS study group. The Italian compassionate use of sofosbuvir in HCV patients waitlisted for liver transplantation: A national real-life experience. *Liver Int*. 2017 Sep 16.

Lionetti R, Calvaruso V, Piccolo P, Mancusi RL, Mazzarelli C, Fagioli S, Montalbano M, Lenci I, Carrai P, Guaraldi G, Visco-Comandini U, Milana M, Biolato M, Loiacono L, Valente G, Craxì A, Angelico M, D'offizi G. Sofosbuvir plus daclatasvir with or without ribavirin is safe and effective for post-transplant hepatitis C recurrence and severe fibrosis and cirrhosis: A prospective study. *Clin Transplant*. 2017 Nov 29.

Mazzarelli C, Cannon M.D., Belli L, Agarwal K. Direct-acting antiviral therapy in patients with hepatocellular cancer: the timing of treatment is everything. *J Hepat* 2017. Sep 1. Epub ahead of print.

Vigano R, Mazzarelli C, Perricone G, Alberti A, Belli C. Change of liver transplantation list composition: pre versus post direct-acting antivirals era. The Niguarda experience. *Dig Liv Disease*. In press.

Donato MF, Morelli C, Romagnoli R, Invernizzi F, Mazzarelli C, Iemmolo RM, Montalbano

M, Lenci I, Bhoori S, Pieri G, Berardi S, Caraceni P, Martini S; ITACOPS-SOF Bridging Study Group. Prevention of hepatitis C recurrence by bridging sofosbuvir/ribavirin from pre- to post-liver transplant: a real-life strategy. *Liver Int.* 2016 Nov 19

Zavaglia C, Okolicsanji S, Cesarini L, Mazzarelli C, Pontecorvi V, Ciaccio A, Strazzabosco M, Belli LS. Is the risk of neoplastic recurrence increased after prescribing Direct Acting Antivirals for HCV patients whose HCC was previously cured? *J Hepatol.* 2016 Aug 31.

Cortesi PA, Mantovani LG, Ciaccio A, Rota M, Mazzarelli C, Cesana G, Strazzabosco M, Belli LS. Cost-Effectiveness of New Direct-Acting Antivirals to Prevent Post-Liver Transplant Recurrent Hepatitis. *Am J Transplant.* 2015 Jul;15(7):1817-26.

Foschi A, Zavaglia CA, Fanti D, Mazzarelli C, Perricone G, Vangeli M, Viganò R, Belli LS. Autoimmunity after liver transplantation: a frequent event but a rare clinical problem. *Clin Transplant.* 2015 Feb;29(2):161-6

Galati G, De Vincentis A, Ripetti V, La Vaccara V, Vespasiani-Gentilucci U, Mazzarelli C, Gallo P, Luppi G, Grasso RF, Picardi A. Haemorrhoidal disease in severe portal hypertension: a combined approach with transjugular intrahepatic portosystemic shunt (TIPS) and transanal haemorrhoidal dearterialization (THD). *Arch Med Sci.* 2014 Feb 24;10(1):195-6.

Perricone G, Mancuso A, Belli LS, Mazzarelli C, Zavaglia C. Sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation: does mTOR inhibitors association augment toxicity? *Eur J Gastroenterol Hepatol.* 2014 May;26(5):577-8.

Vespasiani-Gentilucci U, Carotti S, Perrone G, Mazzarelli C, Galati G, Onetti-Muda A, Picardi A, Morini S. Hepatic toll-like receptor 4 expression is associated with portal inflammation and fibrosis in patients with NAFLD. *Liver Int.* 2015 Feb;35(2):569-81.

Perricone G, Mazzarelli C. Images in clinical medicine. Reexpansion pulmonary edema after thoracentesis. *N Engl J Med.* 2014 Mar 20;370(12):e19.

Zavaglia C, Silini E, Mangia A, Airoidi A, Piazzolla V, Vangeli M, Stigliano R, Foschi A, Mazzarelli C, Tinelli C. Prognostic factors of hepatic decompensation and hepatocellular carcinoma in patients with transfusion-acquired HCV infection. *Liver Int.* 2014 Aug;34(7):e308-16.

Caremani M, Occhini U, Caremani A, Tacconi D, Lapini L, Accorsi A, Mazzarelli C. Focal splenic lesions: US findings. *J Ultrasound.* 2013 May 4;16(2):65-74.

Mancuso A, Mazzarelli C, Perricone G, Zavaglia C. Sorafenib efficacy for treatment of HCC recurrence after liver transplantation is an open issue. *J Hepatol.* 2014 Mar;60(3):681.

Riva E, Scagnolari C, Monteleone K, Selvaggi C, Picardi A, Mazzarelli C, Pizzigallo E, Vincenzi B, Carducci A, Antonaci S, Giannelli G, Antonelli G. Interleukin-28B (IL-28B) single-nucleotide polymorphisms and interferon plus ribavirin treatment outcome in Italian chronically HCV-infected patients. *J Viral Hepat.* 2012 Sep;19(9):650-3.

Casale M, Mazzarelli C, Vespasiani Gentilucci U, Potena M, Pappacena M, Faiella F, Galati G, Salvinelli F, Picardi A. Distortion-product otoacoustic emissions: a useful test for monitoring ototoxicity induced by pegylated interferon and ribavirin treatment in patients with chronic hepatitis C. *Int J Immunopathol Pharmacol*. 2012 Apr-Jun;25(2):551-6.

Gentilucci UV, Gallo P, Perrone G, Del Vescovo R, Galati G, Spataro S, Mazzarelli C, Pellicelli A, Afeltra A, Picardi A. Non-cirrhotic portal hypertension with large regenerative nodules: a diagnostic challenge. *World J Gastroenterol*. 2011 May 28;17(20):2580-4.

Vespasiani-Gentilucci U, Galati G, Mazzarelli C, D'Avola D, Spataro S, Gallo P, Rigon A, Pellicelli A, Dicuonzo G, Afeltra A, Picardi A. Angiogenic cytokines in patients undergoing antiviral treatment for chronic hepatitis C virus infection. *J Interferon Cytokine Res*. 2011 Feb;31(2):207-10.

Picardi A, Gentilucci UV, Bambacioni F, Galati G, Spataro S, Mazzarelli C, D'Avola D, Fiori E, Riva E. Lower schooling, higher hepatitis C virus prevalence in Italy: an association dependent on age. *J Clin Virol*. 2007 Oct;40(2):168-70.

ABSTRACTS

Pasulo L, Mazzarelli C, Iegri C, De Carlis L, Viganò R, Donato F, Burra P, Gambato M, Faggioli S, Belli LS. Pre-emptive post-liver transplant hepatitis C virus treatment with daas: proof of concept from a pilot study. *EASL ILC 2017 (Poster presentation)*. Amsterdam 17/04/2017.

Mazzarelli C, Childs K, Montegue S, Dusheiko G, Agarwal K and Cannon MD. Weight based ribavirin with sofosbuvir and daclatasvir for 12 weeks for patients with Genotype 3 Hepatitis C and cirrhosis: An analysis of efficacy and long-term clinical outcomes. *AASLD 2017 (Poster presentation) ID 1556*. Washington 22/10/2017.

Mazzarelli C, Considine A, Childs K, Carey I, Suddle A, Dusheiko G, Agarwal K and Cannon MD. Does age matter? Direct-acting antiviral therapy for hepatitis C in a real-life cohort of elderly patients: pretreatment drug-drug interactions, tolerability and efficacy of current treatment regimens. *AASLD 2017 (Poster presentation) ID 1557*. Washington 22/10/2017

Mazzarelli C, Cannon MD, Heaton N, Sarker D, Kane P, Quaglia A, Suddle A. Hepatocellular Carcinoma as a complication of vascular disease of the liver after Fontan procedure. *EASL HCC Summit 2018 (Poster presentation)*. Geneva 03/03/2018.

Montegue S, Mazzarelli C, Tsai-Wing Oh, Childs K, Agarwal K and Cannon MD. "How do you feel about your diagnosis of Hepatitis C today?" The emotional benefits of direct-acting antiviral therapy. *EASL ILC 2018 (Poster Presentation)*. Paris 12/04/2018.

Mazzarelli C, Bruce M, Imbert S, Cannon MD, Dusheiko G, Agarwal K, Carey I. Direct fibrosis markers kinetic in patients undergoing antiviral treatment with DAA for chronic hepatitis C. *EASL ILC 2018 (Poster presentation)*. Paris 13/04/2018

Mazzarelli C, Carey I, Childs K, Suddle A, Manini MA, Dusheiko G, Agarwal K and Cannon MD. Predictors of clinical improvement among HCV patients with advanced liver disease treated with DAA: a single center experience. *EASL ILC 2018 (Poster presentation)*.

presentation). Paris 13/04/2018.

PERSONAL SKILLS

Mother tongue(s) Italian

Other language(s)

UNDERSTANDING		SPEAKING		WRITING
Listening	Reading	Spoken interaction	Spoken production	
C2	C2	C1	C1	C1
English*				

*IELTS Certification (11/2017)

Il sottoscritto è a conoscenza che, ai sensi dell'art. 76 del DPR 445/2000, le dichiarazioni mendaci, la falsità negli atti e l'uso di atti falsi sono puniti ai sensi del codice penale e delle leggi speciali. Il sottoscritto autorizza al trattamento dei dati personali, secondo quanto previsto dal Regolamento UE n. 679/2016 - GDPR General Data Protection Regulation, D.Lgs 196/2003 modificato da D.Lgs 101/2018."

"Ai sensi e per effetto del Regolamento (UE) 2016/679 DEL PARLAMENTO EUROPEO E DEL CONSIGLIO del 27 aprile 2016 relativo alla protezione delle persone fisiche con riguardo al trattamento dei dati personali, autorizzo al trattamento dei dati e delle informazioni contenute nel curriculum vitae ai fini del procedimento ECM, consapevole che il CV verrà incluso nell'allegato all'atto della validazione della richiesta di accreditamento, e che sarà visibile nella Banca Dati del sito ECM, accessibile a tutti gli utenti e tramite INTERNET (motori di ricerca). Autorizzo altresì il trattamento ai fini della trasmissione (successiva allo svolgimento dell'evento formativo) alla Commissione Nazionale per la Formazione Continua"

Milano, 24/05/2023